Biotech Values

[JohnWayne]

MRK - On the one hand, I agree, but on the other hand, I wasn't too surprised insofar as I could see the NCCN wanting a more robust dataset before making a recommendation in favor of Keytruda + chemo for 1L NSCLC, especially with the Phase 3 KEYNOTE-189 trial set to report out later in 2017.

In any event, this seems to position MRK as the clear leader in terms of timing for 1L NSCLC, regardless of PD-L1 expression. Will be interesting to see if/how the rest of the class will be able to make up for the timing disadvantage in terms of differentiation, either based on data or marketing activities.